GENMAB A/S/S (OTCMKTS:GMXAY) Stock Price Crosses Below 50 Day Moving Average – Here’s Why

GENMAB A/S/S (OTCMKTS:GMXAY) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $26.89 and traded as low as $24.69. GENMAB A/S/S shares last traded at $25.15, with a volume of 2,085,802 shares.

GENMAB A/S/S Stock Down 0.6%

The firm has a 50 day simple moving average of $26.87 and a 200 day simple moving average of $29.34.

GENMAB A/S/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.